MarketIQ Analyst Report for EUDA Health Holdings Limited

C/O 6 EU TONG SEN STREET, #08-13 THE CENTRAL, SINGAPORE, SG
EUDA

Last Updated: 14 Nov 2024

Executive Summary

EUDA Health Holdings Limited (EUDA) is a publicly traded company in the real estate and construction sector, specifically in the blank checks industry. The company is headquartered in Singapore. EUDA's stock is currently trading at $4.23, with a market capitalization of $157.9 million.

Company Overview

EUDA Health Holdings Limited is a special purpose acquisition company (SPAC). The company was founded in 2021 and raised $150 million in its initial public offering (IPO). EUDA's stated purpose is to acquire a target business in the healthcare industry.

Fundamental Analysis

EUDA's financial performance has been mixed since its IPO. The company has reported losses in each of its first two quarters as a public company. Revenue has also declined sequentially in each of the past two quarters. EUDA's balance sheet is also weak. The company has more liabilities than assets, and its cash position is dwindling.

Technical Analysis

EUDA's stock price has been in a downtrend since its IPO. The stock has fallen below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.

Short Term Outlook

The short-term outlook for EUDA is bearish. The stock is in a downtrend and has broken below key technical support levels. The RSI is also below 50, indicating that the stock is oversold.

Long Term Outlook

The long-term outlook for EUDA is uncertain. The company has yet to acquire a target business, and its financial performance has been weak. However, the healthcare industry is a large and growing market, and EUDA could potentially benefit from this growth if it is able to successfully acquire a target business.

Analyst Recommendations

Analysts are divided on EUDA. Some analysts believe that the stock is undervalued and has potential for growth. Other analysts are more cautious, citing the company's weak financial performance and uncertain long-term outlook. Overall, the analyst consensus is to hold EUDA.